Magnetic phase diagram of Fe1.1Te1-xSex: A comparative study with the stoichiometric superconducting FeTe1-xSex system

We report a comparative study of the series Fe1.1Te1-xSex and the stoichiometric FeTe1-xSex to bring out the difference in their magnetic, superconducting and electronic properties. The Fe1.1Te1-xSex series is found to be magnetic and its microscopic properties are elucidated through Moessbauer spectroscopy. The magnetic phase diagram of Fe1.1Te1-xSex is traced out and it shows the emergence of spin-glass state when the antiferromagnetic state is destabilized by the Se substitution. The isomer shift and quadrupolar splitting obtained from the Moessbauer spectroscopy clearly brings out the electronic differences in these two series.Comment: 6 pages, 9 figure

Ultrasound intensification suppresses the need of methanol excess during the biodiesel production with Lipozyme TL-IM

The synthesis of biodiesel from sunflower oil and methanol based on transesterification using the immobilized lipase from Thermomyces lanuginosus (Lipozyme TL-IM) has been investigated under silent conditions and under an ultrasound field. Ultrasound assisted process led to reduced processing time and requirement of lower enzyme dosage. We found for the first time that ratio 1:3 (oil to methanol) was favoured for the ultrasound assisted enzymatic process which is lower as that favoured for the silent process (ratio of 1.4). Our results indicate that intensification provided by ultrasound suppresses the need of the excess of the methanol reactant during the enzymatic biodiesel production. Ultrasound assisted enzymatic biodiesel production is therefore a faster and a cleaner processes.The authors acknowledge Brenntag India Pvt. Ltd. for kindly providing gift sample of lipase enzyme Lipozyme TL IM to carry out the research work. All authors acknowledge the funding of Department of Science and Technology and Portuguese Science Foundation under the Indo-Portuguese collaborative program

Enteral lactoferrin supplementation for very preterm infants: a randomised placebo-controlled trial

Background Infections acquired in hospital are an important cause of morbidity and mortality in very preterm infants. Several small trials have suggested that supplementing the enteral diet of very preterm infants with lactoferrin, an antimicrobial protein processed from cow's milk, prevents infections and associated complications. The aim of this large randomised controlled trial was to collect data to enhance the validity and applicability of the evidence from previous trials to inform practice. Methods In this randomised placebo-controlled trial, we recruited very preterm infants born before 32 weeks' gestation in 37 UK hospitals and younger than 72 h at randomisation. Exclusion criteria were presence of a severe congenital anomaly, anticipated enteral fasting for longer than 14 days, or no realistic prospect of survival. Eligible infants were randomly assigned (1:1) to receive either enteral bovine lactoferrin (150 mg/kg per day; maximum 300 mg/day; lactoferrin group) or sucrose (same dose; control group) once daily until 34 weeks' postmenstrual age. Web-based randomisation minimised for recruitment site, gestation (completed weeks), sex, and single versus multifetal pregnancy. Parents, caregivers, and outcome assessors were unaware of group assignment. The primary outcome was microbiologically confirmed or clinically suspected late-onset infection (occurring >72 h after birth), which was assessed in all participants for whom primary outcome data was available by calculating the relative risk ratio with 95% CI between the two groups. The trial is registered with the International Standard Randomised Controlled Trial Number 88261002. Findings We recruited 2203 participants between May 7, 2014, and Sept 28, 2017, of whom 1099 were assigned to the lactoferrin group and 1104 to the control group. Four infants had consent withdrawn or unconfirmed, leaving 1098 infants in the lactoferrin group and 1101 in the sucrose group. Primary outcome data for 2182 infants (1093 [99·5%] of 1098 in the lactoferrin group and 1089 [99·0] of 1101 in the control group) were available for inclusion in the modified intention-to-treat analyses. 316 (29%) of 1093 infants in the intervention group acquired a late-onset infection versus 334 (31%) of 1089 in the control group. The risk ratio adjusted for minimisation factors was 0·95 (95% CI 0·86–1·04; p=0·233). During the trial there were 16 serious adverse events for infants in the lactoferrin group and 10 for infants in the control group. Two events in the lactoferrin group (one case of blood in stool and one death after intestinal perforation) were assessed as being possibly related to the trial intervention. Interpretation Enteral supplementation with bovine lactoferrin does not reduce the risk of late-onset infection in very preterm infants. These data do not support its routine use to prevent late-onset infection and associated morbidity or mortality in very preterm infants. Funding UK National Institute for Health Research Health Technology Assessment programme (10/57/49)

Diffuse interface models of solidification with convection: The choice of a finite interface thickness

The thin interface limit aims at minimizing the effects arising from a numerical interface thickness, inherent in diffuse interface models of solidification and microstructure evolution such as the phase field model. While the original formulation of this problem is restricted to transport by diffusion, we consider here the case of melt convection. Using an analysis of the coupled phase field-fluid dynamic equations, we show here that such a thin interface limit does also exist if transport contains both diffusion and convection. This prediction is tested by comparing simulation studies, which make use of the thin-interface condition, with an analytic sharp-interface theory for dendritic tip growth under convection. © 2020, The Author(s)

Enteral lactoferrin supplementation for very preterm infants: a randomised placebo-controlled trial

Background Infections acquired in hospital are an important cause of morbidity and mortality in very preterm infants. Several small trials have suggested that supplementing the enteral diet of very preterm infants with lactoferrin, an antimicrobial protein processed from cow's milk, prevents infections and associated complications. The aim of this large randomised controlled trial was to collect data to enhance the validity and applicability of the evidence from previous trials to inform practice. Methods In this randomised placebo-controlled trial, we recruited very preterm infants born before 32 weeks' gestation in 37 UK hospitals and younger than 72 h at randomisation. Exclusion criteria were presence of a severe congenital anomaly, anticipated enteral fasting for longer than 14 days, or no realistic prospect of survival. Eligible infants were randomly assigned (1:1) to receive either enteral bovine lactoferrin (150 mg/kg per day; maximum 300 mg/day; lactoferrin group) or sucrose (same dose; control group) once daily until 34 weeks' postmenstrual age. Web-based randomisation minimised for recruitment site, gestation (completed weeks), sex, and single versus multifetal pregnancy. Parents, caregivers, and outcome assessors were unaware of group assignment. The primary outcome was microbiologically confirmed or clinically suspected late-onset infection (occurring >72 h after birth), which was assessed in all participants for whom primary outcome data was available by calculating the relative risk ratio with 95% CI between the two groups. The trial is registered with the International Standard Randomised Controlled Trial Number 88261002. Findings We recruited 2203 participants between May 7, 2014, and Sept 28, 2017, of whom 1099 were assigned to the lactoferrin group and 1104 to the control group. Four infants had consent withdrawn or unconfirmed, leaving 1098 infants in the lactoferrin group and 1101 in the sucrose group. Primary outcome data for 2182 infants (1093 [99·5%] of 1098 in the lactoferrin group and 1089 [99·0] of 1101 in the control group) were available for inclusion in the modified intention-to-treat analyses. 316 (29%) of 1093 infants in the intervention group acquired a late-onset infection versus 334 (31%) of 1089 in the control group. The risk ratio adjusted for minimisation factors was 0·95 (95% CI 0·86–1·04; p=0·233). During the trial there were 16 serious adverse events for infants in the lactoferrin group and 10 for infants in the control group. Two events in the lactoferrin group (one case of blood in stool and one death after intestinal perforation) were assessed as being possibly related to the trial intervention. Interpretation Enteral supplementation with bovine lactoferrin does not reduce the risk of late-onset infection in very preterm infants. These data do not support its routine use to prevent late-onset infection and associated morbidity or mortality in very preterm infants. Funding UK National Institute for Health Research Health Technology Assessment programme (10/57/49)

Thin interface limit of the double-sided phase-field model with convection

The thin interface limit of the phase-field model is extended to include transport via melt convection. A double-sided model (equal diffusivity in liquid and solid phases) is considered for the present analysis. For the coupling between phase-field and Navier-Stokes equations, two commonly used schemes are investigated using a matched asymptotic analysis: (i) variable viscosity and (ii) drag force model. While for the variable viscosity model, the existence of a thin interface limit can be shown up to the second order in the expansion parameter, difficulties arise in satisfying no-slip boundary condition at this order for the drag force model. Nevertheless, detailed numerical simulations in two dimensions show practically no difference in dendritic growth profiles in the presence of forced melt flow obtained for the two coupling schemes. This suggests that both approaches can be used for the purpose of numerical simulations. Simulation results are also compared to analytic theory, showing excellent agreement for weak flow. Deviations at higher fluid velocities are discussed in terms of the underlying theoretical assumptions. © 2020 The Author(s) Published by the Royal Society. All rights reserved.European Space Agency, ESADeutsche Forschungsgemeinschaft, DFGRussian Science Foundation, RSF: 16-11-10095Deutsche Forschungsgemeinschaft, DFGData accessibility. This article has no additional data. Authors’ contributions. All the authors have contributed equally to this work. Competing interests. We declare we have no competing interest. Funding. P.K.G. acknowledges the support by the European Space Agency (ESA) under research project MULTIPHAS grant no. (AO-2004) and the German Aerospace Center (DLR) Space Management undercontract no. 50WM1541 and also from the Russian Science Foundation under project no. 16-11-10095. A.S. and F.V. acknowledges financial support by the German Research Foundation (DFG) under the project no. Va205/17-1

High energy X-γ ray spectrometer on the Chandrayaan-1 mission to the Moon

The Chandrayaan-1 mission to the Moon scheduled for launch in late 2007 will include a high energy X-ray spectrometer (HEX) for detection of naturally occurring emissions from the lunar surface due to radioactive decay of the 238U and 232Th series nuclides in the energy region 20-250 keV. The primary science objective is to study the transport of volatiles on the lunar surface by detection of the 46.5 keV line from radioactive 210Pb, a decay product of the gaseous 222Rn, both of which are members of the 238U decay series. Mapping of U and Th concentration over the lunar surface, particularly in the polar and U-Th rich regions will also be attempted through detection of prominent lines from the U and Th decay series in the above energy range. The low signal strengths of these emissions require a detector with high sensitivity and good energy resolution. Pixelated Cadmium-Zinc-Telluride (CZT) array detectors having these characteristics will be used in this experiment. Here we describe the science considerations that led to this experiment, anticipated flux and background (lunar continuum), the choice of detectors, the proposed payload configuration and plans for its realizatio

Virtual Sign Language Translator

The development of a Virtual Sign Language Translator represents a significant advancement in facilitating communication between hearing and non-hearing individuals, particularly in educational and business settings. This initiative aims to bridge the communication gap by providing real-time translation of sign language into text or speech, enhancing accessibility and inclusivity. The system utilizes advanced technologies such as computer vision, machine learning, and natural language processing to accurately interpret sign language gestures. Users can interact through intuitive interfaces, enabling seamless conversion of sign language into readable or audible formats. By integrating this translator into classrooms, universities, institutions, and business environments, we can promote equal participation and understanding, ensuring that information is accessible to all, regardless of hearing ability

Blood Pressure Management in the Very Preterm Infant:More than Just Millimetres

Despite significant advances in many areas of care, the management of low blood pressure and circulatory compromise in the preterm infant continues to be based on quite limited evidence. Deciding when to intervene, and with what to intervene, remains a conundrum at the bedside. In this chapter we explore the aetiology of low blood pressure, we review assessment strategies including new monitoring modalities that may provide a better understanding of the underlying problem and hence direct more appropriate treatments. The evidence for current therapies is reviewed, including the newer inodilators. The future will see a paradigm shift in our current approach to haemodynamic instability and management.</p